Bright Minds Biosciences Inc. - common stock (DRUG) analyst actions
Rating and price-target actions on DRUG in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DRUG overview →
2 measured DRUG analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH | Press release | +2.15% | +7.63% | |
| Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy | Press release | -0.81% | +1.63% |
Keep exploring
More DRUG: earnings → · SEC filings → · DRUG overview →